Ken Griffin’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $112K | Buy |
+40,200
| New | +$122K | ﹤0.01% | 11907 |
|
|
2025
Q4 | – | Sell |
-12,400
| Closed | -$52.5K | – | 13146 |
|
|
2025
Q3 | $52.5K | Sell |
12,400
-42,400
| -77% | -$160K | ﹤0.01% | 12176 |
|
|
2025
Q2 | $116K | Sell |
54,800
-54,700
| -50% | -$81.8K | ﹤0.01% | 11211 |
|
|
2025
Q1 | $134K | Buy |
109,500
+31,100
| +40% | +$43.6K | ﹤0.01% | 11046 |
|
|
2024
Q4 | $101K | Buy |
78,400
+26,800
| +52% | +$64.2K | ﹤0.01% | 11469 |
|
|
2024
Q3 | $142K | Buy |
51,600
+48,900
| +1,811% | +$120K | ﹤0.01% | 10634 |
|
|
2024
Q2 | $6.1K | Buy |
+2,700
| New | +$8.2K | ﹤0.01% | 13358 |
|
|
2024
Q1 | – | Sell |
-4,400
| Closed | -$7.3K | – | 14864 |
|
|
2023
Q4 | $7.3K | Buy |
+4,400
| New | +$8.53K | ﹤0.01% | 13294 |
|
|
2023
Q3 | – | Sell |
-2,400
| Closed | -$3.46K | – | 14572 |
|
|
2023
Q2 | $3.46K | Sell |
2,400
-900
| -27% | -$1.53K | ﹤0.01% | 13690 |
|
|
2023
Q1 | $6.93K | Sell |
3,300
-1,200
| -27% | -$1.94K | ﹤0.01% | 13772 |
|
|
2022
Q4 | $5.08K | Buy |
+4,500
| New | +$5.99K | ﹤0.01% | 14036 |
|
|
2022
Q3 | – | Sell |
-10,700
| Closed | -$14K | – | 12961 |
|
|
2022
Q2 | $14K | Buy |
+10,700
| New | +$15.4K | ﹤0.01% | 12511 |
|
|
2021
Q4 | – | Sell |
-18,400
| Closed | -$71K | – | 14142 |
|
|
2021
Q3 | $71K | Sell |
18,400
-2,700
| -13% | -$9.15K | ﹤0.01% | 13145 |
|
|
2021
Q2 | $68K | Buy |
+21,100
| New | +$75.1K | ﹤0.01% | 13180 |
|
|
2021
Q1 | – | Sell |
-10,000
| Closed | -$22K | – | 13347 |
|
|
2020
Q4 | $22K | Buy |
+10,000
| New | +$26.2K | ﹤0.01% | 10761 |
|
|
2020
Q1 | – | Sell |
-19,200
| Closed | -$55K | – | 9789 |
|
|
2019
Q4 | $55K | Sell |
19,200
-16,800
| -47% | -$58.4K | ﹤0.01% | 8729 |
|
|
2019
Q3 | $132K | Buy |
36,000
+3,500
| +11% | +$12.7K | ﹤0.01% | 8354 |
|
|
2019
Q2 | $135K | Buy |
+32,500
| New | +$141K | ﹤0.01% | 8406 |
|
|
2019
Q1 | – | Sell |
-20,300
| Closed | -$70K | – | 9487 |
|
|
2018
Q4 | $70K | Sell |
20,300
-15,400
| -43% | -$73.6K | ﹤0.01% | 8393 |
|
|
2018
Q3 | $215K | Sell |
35,700
-13,400
| -27% | -$73.7K | ﹤0.01% | 8108 |
|
|
2018
Q2 | $312K | Buy |
49,100
+31,300
| +176% | +$152K | ﹤0.01% | 7146 |
|
|
2018
Q1 | $84K | Sell |
17,800
-2,800
| -14% | -$13K | ﹤0.01% | 7775 |
|
|
2017
Q4 | $69K | Buy |
+20,600
| New | +$52.1K | ﹤0.01% | 7541 |
|
|
2015
Q4 | – | Sell |
-2,900
| Closed | -$7K | – | 8870 |
|
|
2015
Q3 | $7K | Sell |
2,900
-2,600
| -47% | -$6.13K | ﹤0.01% | 8568 |
|
|
2015
Q2 | $15K | Buy |
+5,500
| New | +$16.6K | ﹤0.01% | 8284 |
|
|
2015
Q1 | – | Sell |
-6,000
| Closed | -$21K | – | 8628 |
|
|
2014
Q4 | $21K | Sell |
6,000
-8,100
| -57% | -$35.8K | ﹤0.01% | 7758 |
|
|
2014
Q3 | $71K | Buy |
14,100
+6,800
| +93% | +$53K | ﹤0.01% | 6662 |
|
|
2014
Q2 | $101K | Sell |
7,300
-8,700
| -54% | -$108K | ﹤0.01% | 6212 |
|
|
2014
Q1 | $245K | Buy |
+16,000
| New | +$228K | ﹤0.01% | 5278 |
|
Other funds holding GALT
VCM
WANY
Ken Griffin's GALT Position: Q1 2026 in Review
Ken Griffin opened a new position in Galectin Therapeutics (GALT) in Q1 2026: 290,360 shares worth $810K. The stake represents ﹤0.01% of the portfolio and ranks #8158 among its holdings. This is a return to the name: Ken Griffin previously reported a position in GALT as recently as Q3 2025.
Ken Griffin first reported a position in GALT in Q2 2014 and has held it in 30 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.
- Ken Griffin held 290,360 shares of Galectin Therapeutics worth $810K as of Q1 2026.
- Galectin Therapeutics was a new Ken Griffin position in Q1 2026.
- Galectin Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8158 holding.
- Ken Griffin first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 30 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.